Summary & Overview
HCPCS J3140: Injection, Testosterone Suspension, up to 50 mg
HCPCS Level II code J3140 denotes an injection of testosterone suspension up to 50 mg, used for delivering testosterone therapy via intramuscular or subcutaneous injection. This code is relevant nationally for clinicians, clinics, and payers because it captures an often-utilized form of testosterone replacement and affects coverage, billing, and reimbursement workflows across payers.
Key payers covered in this discussion include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for injectable testosterone suspension, typical sites of service, and the administrative implications associated with billing this HCPCS Level II code. The analysis highlights common benchmarking topics such as utilization patterns, reimbursement considerations, and prior authorization trends as they relate to injectable testosterone products.
This publication offers practical reference material: an explanation of what J3140 represents, where the service is typically provided, and what payers commonly consider in coverage decisions. Data not available in the input is identified where applicable. The content is intended for billing staff, practice managers, and policy analysts seeking a clear, national-level reference on HCPCS Level II code J3140 and its role in testosterone therapy administration.
Billing Code Overview
HCPCS Level II code J3140 describes an injection of testosterone suspension, up to 50 mg. This code represents an injectable medication service for administration of a testosterone suspension formulation.
-
Service type: Drug administration (injectable medication)
-
Typical site of service: Clinic-based or office-based injection; may also be administered in ambulatory care settings
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult male with hypogonadism presenting for intramuscular testosterone therapy. The patient has laboratory-confirmed low serum testosterone and symptoms such as low libido, fatigue, and decreased muscle mass. The clinical workflow includes a baseline visit for history, physical exam, and laboratory testing (total testosterone, LH, FSH, hematocrit, PSA as clinically indicated). Once testosterone suspension therapy is selected, the clinician documents indication and obtains informed consent. At the treatment visit, nursing verifies identity, allergies, and medication reconciliation. The provider or qualified clinician prepares the J3140 medication (testosterone suspension, up to 50 mg), performs or delegates an intramuscular injection (typically into the gluteal or deltoid muscle), documents lot number and dose, and observes the patient briefly for immediate adverse reactions. Follow-up visits include assessment of symptom response, repeat lab monitoring (testosterone level, hematocrit), and dose adjustments as needed. Typical sites of service include outpatient clinic, physician office, or community health center. Emergency department or inpatient administration is uncommon for routine maintenance therapy.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure |